Infigratinib

About BridgeBio Pharma

BridgeBio Pharma operates as a diversified biotech platform targeting genetic diseases through its innovative hub-and-spoke organizational model. The company has advanced multiple programs into Phase 3 trials, including acoramidis for transthyretin amyloidosis, encaleret for hypoparathyroidism, and infigratinib for achondroplasia. With over 2,000 patients enrolled in clinical trials globally and a pipeline consisting of 100% first-in-class or best-in-class therapies, BridgeBio has established itself as a leader in genetic medicine development.

About BridgeBio Pharma

BridgeBio Pharma operates as a diversified biotech platform targeting genetic diseases through its innovative hub-and-spoke organizational model. The company has advanced multiple programs into Phase 3 trials, including acoramidis for transthyretin amyloidosis, encaleret for hypoparathyroidism, and infigratinib for achondroplasia. With over 2,000 patients enrolled in clinical trials globally and a pipeline consisting of 100% first-in-class or best-in-class therapies, BridgeBio has established itself as a leader in genetic medicine development.

About LianBio

LianBio operates as a strategic bridge, connecting innovative global biopharmaceutical assets with high-growth Asian markets, particularly China. The company leverages its deep regional expertise in development, regulatory affairs, and commercialization to advance a portfolio of clinical-stage and commercial-stage therapies. Its business model mitigates early-stage R&D risk by focusing on de-risked, externally sourced candidates with proof-of-concept data. A key strategic move was the announcement in late 2023 to wind down operations and return capital to shareholders, following a review of its strategic alternatives.

Therapeutic Areas

Other Achondroplasia Drugs